Apyx Medical (APYX) Liabilities and Shareholders Equity (2010 - 2026)

Apyx Medical has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $63.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 4.76% year-over-year to $63.0 million; the trailing twelve-month figure through Mar 2026 stood at $245.4 million (down 2.27% YoY), and the FY2025 full-year result was $66.8 million, up 3.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $63.0 million, down from $66.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $79.2 million in Q4 2023, with the low at $51.8 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $62.0 million across 5 years, with a median of $60.7 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 24.66% — and 2023, when it soared 53.05%.
• Apyx Medical's Liabilities and Shareholders Equity stood at $51.8 million in 2022, then soared by 53.05% to $79.2 million in 2023, then slipped by 18.17% to $64.8 million in 2024, then increased by 3.08% to $66.8 million in 2025, then slipped by 5.71% to $63.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $63.0 million (Q1 2026), $66.8 million (Q4 2025), and $57.4 million (Q3 2025), per Business Quant data.